| 选择性COX-2抑制剂的心血管安全性评价 |
| |
| 引用本文： | 鲍仕慧,周望者. 选择性COX-2抑制剂的心血管安全性评价[J]. 儿科药学杂志, 2005, 11(5): 6-8 |
| |
| 作者姓名： | 鲍仕慧 周望者 |
| |
| 作者单位： | 浙江省温州医学院附属第二医院、育英儿童医院,浙江,温州,325027;浙江省永嘉中医院,浙江,永嘉,325102 |
| |
| 摘 要： | 目的：研究以罗非昔布、塞来昔布、伐地昔布、鲁米昔布为代表的选择性COX-2抑制剂在临床应用的安全性。方法：查询国内外相关文献资料并结合临床实践进行回顾性研究。结果：罗非昔布、塞来昔布、伐地昔布、鲁米昔布等都有增加心血管不良事件的危险，同时罗非昔布的心血管风险要高于塞来昔布。结论：心血管危险是COX-2抑制剂的“类效应”，所以在临床应用这类药物时．应当加强合理的监管措施；仍需对COX-2抑制剂在心血管系统的安全性进行深入研究。
|
| 关 键 词： | COX-2抑制剂 心血管 安全性 罗非昔布 塞来昔布 伐地昔布 |
| 文章编号： | 1672-108X(2005)05-0006-03 |
| 收稿时间： | 2005-05-26 |
| 修稿时间： | 2005-07-12 |
Cardiovascular risk of selective cyclooxygenase-2 inhibitors |
| |
| BAO Shi-hui,ZHOU Wang-zhe. Cardiovascular risk of selective cyclooxygenase-2 inhibitors[J]. Journal of Pediatric Pharmacy, 2005, 11(5): 6-8 |
| |
| Authors: | BAO Shi-hui ZHOU Wang-zhe |
| |
| Abstract: | Objective: To study the clinical safety of selective cyclooxygenase-2 inhibitors which mainly include rofecoxib,celecoxib,valdecoxib and lumiracoxib.Methods: The related literatures were searched for and analyzed retrospectively with clinical practice.Results: The selective cyclooxygenase-2 inhibitors including rofecoxib,celecoxib,valdecoxib and lumiracoxib could increase the risk of cardiovascular event and the risk of rofecoxib was higher than celecoxib.Conclusion: Cardiovascular risk is of class effect of the selective cyclooxygenase-2 inhibitors.Supervision of them in clinical use should be intensified and the cardiovascular safety of these drugs should be investigated further. |
| |
| Keywords: | Cyclooxygenase-2 inhibitor Cardiovascular Safety Rofecoxib Celecoxib Valdecoxib |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
